Elucid Bioimaging Inc. radiology AI products

Turn this list into an evaluation

Each entry is an FDA submission, not a distinct commercial offer. Inspect the exact record before comparing evidence, asking for a quote or planning an integration.

Which exact product, version and licensed modules are in the current offer?
Do related FDA submissions document the same scope, or different functions and versions?
Which costs, support obligations and local acceptance tests remain unresolved?

Prepare with a buyer guide:

Radiology AI pricing and total cost of ownership

Clinical guide links appear when this list contains a current reviewed example. They do not classify or endorse the other entries. All buyer guides · Compare exact records · Documented families

FDA-cleared K221463

ElucidVivo A.3

Elucid Bioimaging Inc.

Authorized purpose: ElucidVivo A.3 postprocesses contrast multidetector CT to visualize arterial vessels and provide semi-automatic lumen boundaries, stenosis and lumen measurements, vessel length, and related values to assist trained physicians in atherosclerosis stratification; measurements complement standard care and are not diagnoses or recommendations.

Modality: CT/CTA
Anatomy: Arterial vessels and atherosclerotic disease
Decision: 2022-06-17

Detection and CADe Quantification and segmentation

FDA-cleared K183012

vascuCAP

Elucid Bioimaging Inc.

Authorized purpose: vascuCAP analyzes contrast multidetector CT of arterial vessels to support atherosclerosis stratification with color maps, three-dimensional views, multiplanar reformats, and measurements for physician review.

Modality: CT/CTA
Anatomy: Heart/Cardiovascular
Decision: 2018-12-21

Cardiac imaging Detection and CADe Quantification and segmentation